Answers are grounded in this paper and cite their sources.
Shows low diagnostic yield of ACC/AHA genetic testing guidelines in thoracic aortic disease, suggesting the need for more targeted screening criteria.
PURPOSE: Thoracic aortic aneurysms (TAA) are typically asymptomatic until rupture or dissection, with research indicating up to 20% may have a genetic basis. This study evaluates the prevalence of hereditary aortopathies and the utility of genetic testing in adults with TAA applying current ACC/AHA guidelines. METHODS: We assessed 1323 consecutive adult patients presenting for TAA evaluation between July 2022 and April 2025 at a large aortic center, enrolling 426 patients who underwent guideline-driven genetic testing. Median (IQR) age was 57 (50-64) years, 22.8% were female, and 11.3% had bicuspid aortic valves. Mean aortic diameter was 4.6 ± 0.48 cm; 67.1% had TAA and 2.1% had dissections. Statistical analyses assessed the prevalence of genetic aortopathies and risk factors. RESULTS: Of the 426 patients, 2.6% had diagnostic tests identifying pathogenic variants, 68.3% tested negative, and 29.1% had variants of unknown significance (VUS). Diagnostic tests were significantly associated with younger age(P = .05) and root aneurysms(P < .001). No VUS associations were demonstrated. Gender and bicuspid aortic valves were not associated with diagnostic tests or VUS. TAA diagnosis < 60 years and familial history had the highest utility of the ACC/AHA recommendations but were not significant. CONCLUSION: Our findings suggest a lower prevalence of genotype-positive TAA than previously reported in all TAA patients; highlighting the need for more refined genetic testing criteria focusing on high-risk individuals. Further research is essential to better define genetic testing's role in TAA management.
No takes yet. Share an insight, caveat, or question.
Jabagi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: